Bedaquiline, a new antituberculosis drug, has already been used in> 50 countries. The
emergence of bedaquiline resistance is alarming, as it may result in the rapid loss of this …

The World Health Organization's End TB Strategy prioritizes universal access to an early
diagnosis and comprehensive drug susceptibility testing (DST) for all individuals with …

Abstract Drug-resistant (DR)-TB is the major challenge confronting the global TB control
programme, necessitating treatment with second-line anti-TB drugs, often with limited …

This article provides an encompassing review of the current pipeline of putative and
developed treatments for tuberculosis, including multidrug-resistant strains. The review has …

The FDA granted expedited approval for Johnson and Johnson's Bedaquiline to treat
pulmonary multidrug resistant tuberculosis on 28 December 2012 which is more common in …

Background Non-tuberculous mycobacteria (NTM) infections are hard to treat. New
antimicrobial drugs and smarter combination regimens are needed. Objectives Our aim was …

Acquired drug resistance by Mycobacterium tuberculosis (MTB) may result in treatment
failure and death. Bedaquiline was recently approved for the treatment of multidrug-resistant …

Since the last 4 decades, Bedaquiline has been the first drug discovered as a new kind of
anti-tubercular agent and received FDA approval in December 2012 to treat pulmonary multi …

Although tuberculosis (TB) is preventable and curable, the lengthy treatment (generally 6
months), poor patient adherence, high inter-individual variability in pharmacokinetics (PK) …

Bedaquiline (BDQ, B) is the first-in-class diarylquinoline to be approved for treatment of
tuberculosis (TB). Recent guidelines recommend its use in treatment of multidrug-and …